Area of research
Endocrinology, Diabetes and Metabolism · Surgery
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Adipokines, Inflammation, and Metabolic Diseases, and Cancer, Lipids, and Metabolism.
Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study.
Dysglycaemia and incident aortic stenosis: a cohort study.
Different plasma biomarker patterns associated with coronary atherosclerosis in low- versus high-risk individuals - an observational cross-sectional study.
Concerns of first-year medical students regarding their future profession: an international study.
Enhanced levels of IL-6 and PAI-1 and decreased levels of MMP-3 in cytomegalovirus seropositive patients with prior myocardial infarction.
Inflammatory biomarkers and long-term outcome in young patients three months after a first myocardial infarction.
Associations between inflammatory and angiogenic proteomic biomarkers, and cardiovascular events and mortality in relation to kidney function.
Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease.
Eligibility for lipid-lowering therapy when applying systemic coronary risk estimation 2 according to guidelines on apparently healthy middle-aged individuals.
Association between high-sensitivity C-reactive protein and coronary atherosclerosis in a general middle-aged population
Association between high-sensitivity C-reactive protein and coronary atherosclerosis in a general middle-aged population.
Prognostic importance of biomarkers associated with haemostatic, vascular and endothelial disturbances in acute coronary syndrome patients in relation to kidney function.
Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trial.
Statin Treatment Intensity, Discontinuation, and Long-Term Outcome in Patients With Acute Myocardial Infarction and Impaired Kidney Function.
Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study.
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure
Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction.
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure.
Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c.
Arginase 1 is upregulated at admission in patients with ST-elevation myocardial infarction.
Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013-17.
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry.
Use of proteomics to identify biomarkers associated with chronic kidney disease and long-term outcomes in patients with myocardial infarction.
New candidate genes for ST-elevation myocardial infarction.
Preoperative disturbances of glucose metabolism and mortality after coronary artery bypass grafting.
Corrigendum to "Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis" [Clin. Biochem. 64 (2019) 24-29].
Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis.
Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis